Recurrent disease following high-dose chemotherapy is a major problem in patients with acute myeloid leukemia (AML). To identify its characteristics, we performed expression profiling in blasts from untreated AML and relapse, using a specific cDNA microarray comprising 4128 genes generated by cDNA subtraction supplemented with cancer-associated genes. Expression analysis of 18 AML bone marrow specimens showed that recurrent AML is commonly associated with the mRNA expression changes in a set of 58 genes. Increased cellular proliferation was indicated by the overexpression of the transferrin receptor, proliferating cell nuclear antigen, and G1 cyclins. An immunohistochemical study for Ki-67-positive blasts in 18 paired bone marrow biopsy samples confirmed a highly significant (Po0.0001) increase in the proliferation fraction at relapse. In addition, we found enhanced activation of the RAF/MEK/ERK cascade as mRNAs of MKP-1, c-jun, c-fos, and egr-1 were significantly increased at relapse. Immunohistochemistry and immunoblotting analyses for biphosphorylated ERK1/2 protein provide additional evidence for enhanced activation of the RAF/MEK/ERK pathway. The degree of increase is significantly correlated with the increased proliferation. Furthermore, the genes identified provide a rationale for further studies on predictive diagnosis and therapeutic intervention.
Introduction
High-dose chemotherapy (HDC) brings about complete remission (CR) in approximately 80% of patients with acute myeloid leukemia (AML). This good initial response is offset by a 60% incidence of recurrent disease, which is characterized by an even worse prognosis (Gale et al., 1996; Appelbaum et al., 2001 ).
Compared to AML prior to HDC (AML DX), relapsed AML (AML REL) may demonstrate biological changes responsible for recurrence that either reflect the selection of a pre-existing clone or acquisition of novel changes. Numerous reports have focused on these differences, as they can play an important role in treatment strategies. At relapse, over half of patients demonstrate karyotypic changes in the leukemic blasts, either towards more or less complexity or even reversion to a normal karyotype (Garson et al., 1989; Estey et al., 1995; Hur et al., 2001 ). Acquisition and/or loss of mutations are frequent , and immunophenotypic characteristics of blasts are often altered at the time of disease recurrence (Borella et al., 1979; Pui et al., 1986; Baer et al., 2001) . Changes of expression levels involving putative mechanisms of drug resistance, such as multidrug resistance gene-1 (Pgp) (Marie et al., 1991; Guerci et al., 1995; van den Heuvel-Eibrink et al., 2001) , multidrug resistance-related protein (MRP-1) (Musto et al., 1990) , breast cancer resistance protein (BCRP) (van der Kolk et al., 2002) , and multidrug resistancerelated vault lung resistance protein (LPR) (van den Heuvel-Eibrink et al., 2002) , have been shown, but are not consistently observed in either paired or nonpaired clinical studies.
In AML blasts, many genetic lesions are found upstream the RAF/MEK/ERK cascade, which comprise an orderly signaling cascade in response to a variety of extracellular stimuli implicated in control of different and even opposite cellular responses including proliferation, differentiation, and cell death (Davis, 1993) . For example receptor tyrosine kinases (like fms, c-kit, and flt3) and the GDP/GTPbinding protein RAS have frequently been found to be mutated in AML, leading to ligand-independent activation (Bos et al., 1987; Farr et al., 1988; Radich et al., 1990; Padua et al., 1998; Gari et al., 1999; Kiyoi et al., 1999) . However, common changes in this pathway specific for relapse or refractory disease have not been shown.
Thus, while there is general consensus that relapse or refractory disease is not simply a recurrence of the leukemia initially diagnosed, only very few common molecular changes are described. Common characteristics in AML REL, however, could provide important clues for the understanding of recurrent disease and for rational intervention. In the present study, we attempted to identify 'relapse associated genes' from 18 AML bone marrow specimens. To achieve this, we performed microarray analysis, cDNA subtraction with sequence analysis, and validation of microarray data with quantitative real-time PCR of selected genes. We identified a subset of genes that appeared to be commonly deregulated in AML REL. Further investigation of leukemic blasts using immunohistochemistry and Western blot analysis indicated an increased proliferative potential and an enhanced activation of the RAF/MEK/ERK cascade as a hallmark of recurrent AML after HDC.
Results
Creation of a 'relapse-specific' cDNA microarray With the goal of characterizing changes in gene expression during the development of resistant AML, we created a cDNA microarray that focuses on the differences of AML DX and AML REL. Therefore, we generated a subtracted cDNA library representing deregulated clones at relapse. Libraries were generated and subtracted from a pool of AML DX (n ¼ 6) and a pool of AML REL (n ¼ 6) using the first as a driver, the second as a tester, and vice versa. Following subtraction, we selected 768 clones that were up-, and 768 that were downregulated at AML REL to spot robotically on the microarray. The second goal was to complement the microarray with genes presumed to be relevant for malignancies and relapses, as well as for myeloid differentiation (Figure 1 ).
Gene expression patterns distinguish AML DX and AML REL
We next tested if the cDNA subtraction library was able to represent the differences of AML DX and AML REL. We used a hierarchical clustering algorithm (Hartigan, 1973 ) and a pseudocolor visualization matrix (Weinstein et al., 1997) . We applied two-dimensional hierarchical clustering to the 2-log ratios of the 18 individual patient samples (Table 1) compared to reference RNA from a set of 1291 cDNAs. The 1291 cDNAs were those (of 4128 total) that included no flagged value for each of the 18 hybridization experiments after data preparation. Most notably, the cluster tree clearly divided the 10 AML DX from the eight AML REL samples. The two clinical groups were distinguished by the specific expression of characteristic groups of genes represented in the subtracted library, demonstrating the efficiency of the method (Figure 2a ). For further analyses of the microarray expression data, cDNA clones were considered altered in AML REL if they exhibited a statistically different (Po0.05) and 1.7-fold or greater change in the mean expression compared to AML DX. Clones from the subtracted library achieving these criteria were sequenced and identified ( Figure 1) . After reducing the redundancy of the subtracted clones, we obtained a total of 58 significant deregulated genes (Table 2) , of which the majority, 46 genes, is commonly upregulated in AML REL. Genes differentially expressed in AML REL are implicated in proliferation, signal transduction, cell cycle, cell growth, and interaction with the microenviroment. Quantitative real-time PCR (RQ-PCR) confirmed the expression of b-raf, egr-1, c-fos, and transferrin receptor (TFR), demonstrating the fidelity of the microarray expression analysis (Figure 2b ).
Increased proliferative activity of AML blasts
Proliferation markers present on the microarray included the TFR and proliferating cell nuclear antigen (PCNA). RNA analysis revealed a mean 4.3-fold70.39 increase of TFR expression in AML REL compared to AML DX samples. The PCNA expression was enhanced by a factor of 1.970.31. Blast populations with an increased proliferation fraction should contain a higher percentage of cells in the mid-G1 and early S phase. Indeed, the mean mRNA expression levels of the G1 cyclins, cyclin D1, and cyclin D3 were increased 2.7- Table  1 ). The cDNA subtractions were performed in either direction. A total of 1536 subtracted cDNA clones were immobilized together with 2592 putative cancer relevant clones on a microarray. Hybridization experiments were performed on 18 AML samples (10 AML DX, eight AML REL). After analysis of expression values, subtracted clones were further investigated for sequence identity and redundant clones were excluded. Finally, a subset of relapse specific genes was obtained. RQ-PCR, immunohistochemistry, and immunoblotting confirmed alterations detected by microarray analysis in selected genes. DX indicates diagnosis and REL indicates relapse fold70.25, and 2.8-fold70.33 in AML REL compared to AML DX (Figure 3) .
To verify the increased proliferation, we performed an immunohistochemical study for the expression of the Ki-67 antigen on 18 paired bone marrow biopsies (at diagnosis and at the time of first disease recurrence after HDC) ( Table 1 ). The monoclonal antibody MIB-1 detects the cell proliferation-associated human nuclear antigen Ki-67 and is a marker commonly used for cellular proliferation (Figure 4a and b) . Percentages of blasts reactive with MIB-1 antibody ranged from 12.5 to 100% at diagnosis and from 37.5 to 100% at relapse. Paired analysis revealed a highly significant (Po0.0001) increase of the proliferation fraction in leukemic blasts at relapse (Figure 4c ). This effect was not related to the number of blasts present in the sample since the percentage of leukemic blasts in bone marrow samples was not different between the two groups.
Increased activation of the RAF/MEK/ERK pathway in relapsed/refractory AML Enhanced activity of the RAF/MEK/ERK pathway is associated with increased mRNA levels of MKP-1, cyclin D1, c-jun, c-fos, and egr-1 (Gille et al., 1992; Rozek and Pfeifer, 1993; Hodge et al., 1998; Vinals and Pouyssegur, 1999) . Comparison of expression data from the 10 AML DX bone marrow specimens and the eight AML REL specimens showed a 2.8-fold70.18 increase of MKP-1 in the 'relapse' group. Similarly, cyclin D1 (see above) was increased in relapsed and refractory AML. The ERK-regulated c-jun, c-fos, and Egr-1 mRNA levels were increased, 2.03-fold7 0.15, 3.99-fold70.38, and 5.6-fold70.23, respectively ( Figure 5 ).
The RAF/MEK/ERK pathway activation proceeds through phosphorylation of its components. To verify the activation of this pathway in AML REL, we performed immunohistochemical analysis on nine paired bone marrow samples that were also used for the measurement of the proliferation. Phosphorylated ERK1/2 demonstrated a cytoplasmic and nuclear localization ( Figure 6a and b) consistent with its known bimodal distribution (Chen et al., 1992) . Immunohistochemical signals (graded as þ , þ þ , þ þ þ ) revealed a higher or equal intensity in all relapse specimens compared to diagnosis, indicating increased activation (P ¼ 0.015). The Spearman test demonstrated a significant correlation of increased MIB-1 and increased phosphorylated ERK1/2 positivity in paired AML samples (r ¼ 0.69, P ¼ 0.04) (Figure 6c ). To further substantiate RAF/MEK/ERK activation, a randomly selected set of eight peripheral blood samples containing at least 90% blasts from patients with AML at diagnosis and relapse was analysed by Western blot with the same antibody used for immunohistochemistry. A strong signal was observed in all relapse samples, whereas only bands of low or moderate intensity could be detected in specimens from primary diagnosis ( Figure 6d ).
Discussion
Differences in the gene expression of AML DX and AML REL might reflect pathophysiological mechanisms of recurrent disease. The majority of genetic and 
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Common alterations in gene expression in relapsed AML PB Staber et al phenotypic differences described so far do not show consistent changes when analysed in a larger set of leukemic cases (Borella et al., 1979; Pui et al., 1986; Garson et al., 1989; Estey et al., 1995; Nakano et al., 1999; Baer et al., 2001; Hur et al., 2001) . Data provided by our study using large-scale gene expression profiling add a subset of 58 genes commonly deregulated in AML REL, representing alterations, which might be characteristic for the development of recurrence.
A prominent group of genes deregulated in AML REL points to an increased proliferation potential. First, this is shown by the overexpression of proliferation markers. Expression of the TFR, a transmembrane homodimeric glycoprotein, is associated with proliferation, since it delivers iron into cells, which is required for early biochemical events in proliferation (Terada et al., 1993) . PCNA is widely accepted as an accurate proliferative marker in numerous tissues (Prelich et al., 1987) . Second, an increased proliferation fraction is associated with a higher percentage of cells in the mid-G1 and early S phase that is accompanied by elevated expression of G1 cyclins (Resnitzky et al., 1994) . Overexpression of the cyclin D1 and cyclin D3 mRNA was observed in our studies and point to an induction of the mid-G1 and early S phase of the cell cycle. Furthermore, we demonstrated an increased proliferation fraction of myeloid blasts at the protein level in 18 paired (AML DX and AML REL) bone marrow biopsies by immunohistochemistry using MIB-1 antibody that recognizes Ki-67, a nuclear nonhistone protein.
Drug extrusion by multidrug resistance proteins such as MDR1 (or P-glycoprotein), MRP1, LRP, and BCRP is a well-characterized drug-resistance mechanism, although the clinical significance of their expression remains doubtful (Leith et al., 1999) . In agreement with other paired and nonpaired studies (Musto et al., 1990; Marie et al., 1991; Guerci et al., 1995; van den Heuvel-Eibrink et al., 2001 DX1  DX2  DX4  DX8  DX5  DX6  DX7  DX3  DX9  DX10  REL6  REL1  REL2  REL3  REL4  REL7  REL5  REL8   DX1  DX2  DX4  DX8  DX5  DX6  DX7  DX8  DX9  DX10  REL6  REL1  REL2  REL3  REL4  REL7  REL5 Common alterations in gene expression in relapsed AML PB Staber et al compared to pretreated AML at diagnosis. Also, in agreement with previous reports, Bcl-2, Bcl-XL, and Bax mRNA expression levels were not different in relapsed and refractory disease (Kaufmann et al., 1998) . Bcl-2, Bcl-XL, and MCL-1 have been implicated as negative regulators of apoptosis, whereas their partner protein Bax acts as a positive regulator of apoptosis (Reed, 1997) . Our data (Table 2) confirm the reported increase in MCL-1 mRNA expression at the time of recurrence (Kaufmann et al., 1998) , although its functional consequence appears minor, since the amount of apoptotic cells detected by immunohistochemistry for active form of caspase3 (data not shown) was not different between AML DX and AML REL. Our patient collective demonstrates an increase of cjun, c-fos, and erg-1 mRNAs in relapsed and refractory AML. This indicates, together with increased expression of MKP-1, and cyclin D1, an enhanced activation of the RAF/MEK/ERK cascade in AML at relapse. As seen in Table 2 , additional target genes of the AP-1 transcription factors c-jun and c-fos (i.e. urokinase, thrombospondin, Timp1) are also upregulated in AML REL. Finally, we showed functional pathway activation in AML REL using antibodies specifically recognizing ERK1/2 catalytically activated by phosphorylation at Thr202 and Tyr204. Interestingly, the degree of signal alteration from the individual paired sample showed a significant correlation of increased proliferation and enhanced RAF/MEK/ERK activation. Taken together, these results clearly point to an important role of the RAF/MEK/ERK cascade in AML REL. Alterations in mRNA concentration upstream the cascade were not detected, implicating that events leading to activated RAF/MEK/ERK might be due to mutations of upstream genes. However, a detailed investigation of mutations that might be responsible is beyond the scope of this study, since there are numerous candidate genes upstream the cascade and it is conceivable that the consistently enhanced activation of RAF/MEK/ERK at relapse might be caused by defects differing in every single case.
AML at diagnosis is a highly proliferative neoplasia that can be brought into CR in 80%, but relapses in 60%, which is consistent with the theory of Goldie and Coldman (1983) that the proliferation rate of neoplasia is important since it is correlated with the amount of cells primarily resistant to chemotherapy. This model also fits our observation of a still higher proliferation fraction in AML REL, which shows an even higher rate of recurrence than primary AML.
In summary, leukemic blasts at relapse show an increased proliferation correlated with enhanced RAF/ MEK/ERK activation that might be caused by several different upstream molecular changes. Components of the RAF/MEK/ERK cascade have been discussed recently as a rational target for therapy (for a review, see Lee and McCubrey, 2002 
Patients and methods

Patient population
For microarray analysis, 18 bone marrow samples were obtained: 10 at diagnosis, six upon the first relapse, and two from patients with refractory disease (Table 1) . In three cases, material was available from both diagnosis and relapse/refractory disease (samples DX1-REL1, DX2-REL2, DX10-REL8). Immunohistochemistry for the human Ki-67 antigen (MIB-1) expression was performed on paired bone marrow biopsies from the iliac crest of 18 patients at diagnosis and upon the first relapse (12) or in refractory disease (6, Table 1 ). For protein expression analysis of phospho-p44/42 map kinase, nine paired samples out of these 18 were available. All patients provided written informed consent and their treatment conformed to the Helsinki declaration. Induction therapy consisted of either idarubicin 12 mg/m 2 /day (days 1-3) combined with continuous infusion of cytarabine 200 mg/m 2 /day (days 1-5) (IA) or mitoxantrone 10 mg/m 2 /day (days 1-3) combined with cytarabine 1.0 or 2.0 g/m 2 /12 h Â 6 (cHAM). Postremission therapy consisted of one or two cycles IA or cHAM. Fludarabine 30 mg/m 2 /day þ cytarabine 2 g/m 2 / day (days 1-5) and G-CSF 5 mg/kg/day (FLAG) was given as a second-line treatment. The criteria for CR were achievement of platelet count 4100 000/ml, neutrophil count 41000/ml, and bone marrow with o5% blasts.
Sample preparation
For microarray analysis, we used bone marrow biopsies that showed at least 80% infiltration by myeloid blasts. Immediately after harvest, samples were placed in RNA (Ambion, Austin, TX, USA) and later stored at À801C until they were homogenized with an Ultraturrax homogenizer (IKA Laboratory Technology, Staufen, Germany). The total RNA was isolated using Trizol Reagent (Life Technologies, Carlsbad, CA, USA), and RNA integrity was verified by denaturing agarose gel electrophoresis.
Generation of subtracted cDNA library via suppression subtractive hybridization (SSH)
The total RNA was pooled from six samples at diagnosis (DX1-DX6, Table 1 ) and from six samples at relapse (REL1-REL6, Table 1 ). Poly(A) þ RNA was isolated using Oligotex m-RNA spin columns (Qiagen, Valencia, CA, USA). cDNA synthesis and subtraction were performed using the PCRSelect cDNA Subtraction Kit (Clontech, Paolo Alto, CA, USA) according to the manufacturer's protocol. The resulting subtracted cDNAs were cloned into pCR 2.1 Vector (Invitrogen, Carlsbad, CA, USA) and transformed into E. coli XL-1 Blue (Invitrogen) to generate the 'relapse'-cDNA library. 
Colony PCR and microarray generation
For microarray generation, 1536 colonies (containing 768 up-and 768 downregulated cDNAs) were randomly selected from the 'relapse'-cDNA library. In addition, IMAGE cDNA clones were purchased from RZPD (Berlin, Germany), and verified by DNA sequencing. These clones were chosen to represent genes presumed to be relevant for malignancies and relapses, as well as for myeloid differentiation. Two plant clones, cab and rbcl (Stratagene, Amsterdam, Netherlands), were included as external standards. All 4128 clones were processed according to the standard protocols (Hegde et al., 2000) and printed onto Corning CMT-GAPS tm aminosilane-coated glass microscope slides (Corning Life Sciences, Schiphol-Rijk, Netherlands), using a GMS 417 Arrayer (Genetic MicroSystems, Woburn, MA, USA).
Microarray analysis
A total of 18 microarray hybridization experiments were performed using Universal Human Reference RNA (Stratagene) as the Cy 3-labeled reference. A measure of 20 mg of this reference as well as the total RNA from AML samples were mixed with varying amounts (15 or 45 pg) of cab and rbcl plant gene mRNAs (Stratagene) and fluorescently labeled with Cy 3 or Cy 5 dCTP by reverse transcription. Finally, Cy 3-and Cy 5-labeled probes were mixed and applied to the microarray for hybridization at 421C for 12-16 h followed by several washing steps.
Hybridized microarrays were scanned using a GMS 418 Array Scanner (Genetic MicroSystems) and fluorescent images were analysed using ImaGene4.1 software (BioDiscovery, Los Angeles, CA, USA). The photomultiplier tube and the laser value for scanning were calibrated over all spots in both the Cy 3 and Cy 5 channels. The ratios were calibrated by applying normalization factors calculated from the mean intensities over all spots after local background correction using GeneSight3.0 software (BioDiscovery). Spiked plant gene signals were used to validate normalization. To verify positive spots and those flagged as false, empty, or poor spots, an additional survey was performed manually. For identification of deregulated genes in AML REL compared to AML DX, the ratios of the individual samples compared to the reference RNA were used.
Real-time quantitative RT-PCR (RQ-PCR)
RQ-PCR analyses were performed using the GeneAmp 5700 Sequence Detection System instrument and software (Applera, Foster City, CA, USA). Assays-onDemand primers and probes (Applera) were used for TFR, b-raf, egr-1, c-fos, and abl. The relative expression levels of the genes of interest were computed with respect to abl to normalize for variations in the quality of the RNA and the amount of input cDNA. Ct (cycle threshold) was used for quantification of the input target number, and all experiments were performed with triplicates for each data point. Patient samples with a variation of 40.5 Ct for the triplicate were retested. For each experimental sample, the amount of target and endogenous reference was determined from a standard curve. The standard curve was constructed with fivefold serial dilutions of cDNA (1000-1 ng) from Universal Human Reference RNA (Stratagene). The level of expression of the target gene was given by the N-ratio, in which each normalized gene value was divided by a calibrator normalized gene value (abl). PCR was carried out with 1 Â TaqMan Universal PCR Master Mix (Applera), 2.5 ml 20 Â Assay-on-Demand (primer and probe), and 5 ml of each appropriately diluted reverse transcription sample in a 50-ml final reaction mixture. After incubation for 2 min at 501C and 10 min at 951C, each of the 40 PCR cycles consisted of 15 s of denaturation at 951C and hybridization of probe and primers for 1 min at 601C. 
Immunohistochemistry
Immunohistochemistry was performed on fresh frozen bone marrow biopsy specimens using the MIB-1 antibody (Dako, Glostrup, Denmark) (Gerdes et al., 1984) , and phospho-p44/42 map kinase antibody (Cell Technology, Beverly, MA, USA) targeting exclusively ERK1/2 phosphorylated at threonine 202 and tyrosine 204. The primary antibodies were diluted 1 : 100 (MIB-1) in antibody diluent (Dako) and 1 : 100 (phospho-p44/42 map kinase) in primary antibody diluent 'Monet blue' (Biocarta, Carlsbad, CA, USA), respectively. The alkaline phosphatase antialkalinephosphatase (APAAP) method was used for detection (Cordell et al., 1984) . Specimens were counterstained with hematoxylin and were assessed independently by two pathologists (GH, CB-S) in a blinded study. For each biopsy, 10 high-power fields containing at least 500 blasts were evaluated. The proliferation fraction of myeloid blasts is given as the percentage of blasts positive for MIB-1. Only clear nuclear signals were considered to be positive. Since all blasts in a given sample showed homogeneous staining intensity for phosphorylated ERK1/2, it was graded on an arbitral scale and is reported as þ , þ þ , or þ þ þ .
Western immunoblotting
Cell pellets with more than 90% leukemic blasts obtained from the peripheral blood of eight patients were lysed directly in protein sample buffer (2% sodium dodecyl sulfate (SDS), 62. 
Statistics
Gene expression analysis was performed using GeneSight3.0 (BioDiscovery) and Genesis1.1.3 (University of Technology, Graz, Austria). Gene trees were generated by hierarchical clustering using the standard correlation (Pearson's correlation around zero) with a separation ratio of 0.5 and a minimum distance of 0.001. To calculate differences in mRNA levels in the experimental groups, the t-test was used after normal distribution was confirmed. Differences in the proliferation fraction between diagnosis (DX) and relapsed/refractory AML (REL) were assessed with paired-samples t-test. The
Wilcoxon test was used to detect differences in p-ERK1/ 2 signals. The Spearman correlation test was performed on delta values (AML REL-AML DX) of MIB-1 and p-ERK1/2 signals, respectively. Significance was considered when the P-value was o 0.05.
